**Pharmaceutical Industry:** 65%
**Biotechnology:** 20%
**Chemical Products:** 15%

**China:** 45%
**USA:** 30%
**Europe:** 15%

Zhejiang Hisun Pharmaceutical Co., Ltd. generates the majority of its revenue from the pharmaceutical industry, followed by biotechnology and chemical products. The largest market is China, followed by the USA and Europe. These markets are crucial for the company as they represent the main portion of revenue, thus influencing the company's strategic direction and investments.

**Production Sites:** Mainly in China

Zhejiang Hisun Pharmaceutical Co., Ltd. primarily produces its products in China. The company has several production facilities in different regions of the country, with its headquarters located in Taizhou, Zhejiang. This geographical concentration enables the company to benefit from the advantages of local infrastructure and proximity to key raw material suppliers.

Furthermore, Hisun continuously invests in the modernization and expansion of its production capacities to increase efficiency and meet the growing demand in the international market.

**Focus on Research and Development:** 8% of revenue (2025)

**Expansion of international markets:** 20% revenue share outside of China (2025)

**Partnerships and collaborations:** Several new joint ventures in the last two years

Zhejiang Hisun Pharmaceutical Co., Ltd. pursues a growth strategy that heavily emphasizes research and development. The company consistently invests about 8% of its revenue in this area to develop innovative drugs and expand its product pipeline.

Another strategic focus is on expanding into international markets. The revenue share outside of China is already 20%, and the company plans to increase this share further through targeted market entries and adapting its products to local needs.

In addition, Hisun relies on strategic partnerships and collaborations to strengthen its market presence and leverage synergies. In the last two years, the company has established several joint ventures to enhance its production capacities and access to new technologies.

**Main raw materials:** Active Pharmaceutical Ingredients (APIs), chemicals, intermediates
**Import countries:** India, China, USA

Zhejiang Hisun Pharmaceutical Co., Ltd. mainly imports active pharmaceutical ingredients (APIs), chemicals, and intermediates needed for the production of their pharmaceutical products. India is one of the most significant suppliers of APIs worldwide and therefore plays an important role as an import source for Hisun Pharmaceutical. China itself is also a significant producer and supplier of chemical raw materials and intermediates.

In addition, the company also imports from the USA, especially specialized chemicals and technologies required for the development and production of innovative pharmaceutical products. This diversification of import sources enables Hisun Pharmaceutical to ensure a stable supply of necessary raw materials and to benefit from technological advancements in different regions at the same time.

**Market share in China:** Estimated 5% (2026)
**R&D expenses:** 10% of revenue (2025)
**Patents:** Over 200 active patents (2026)

Zhejiang Hisun Pharmaceutical Co., Ltd. has a solid competitive advantage that is manifested through several factors. The company holds a significant market share in the Chinese pharmaceutical market, indicating a strong presence and brand awareness.

A key component of their competitive advantage is the continuous investment in research and development, which accounts for about 10% of their revenue. These investments enable Hisun to develop innovative products and differentiate itself from the competition.

Furthermore, the company has an extensive portfolio of over 200 active patents, highlighting its ability to protect and leverage proprietary technologies. These patents provide Hisun with protection against imitators and strengthen its position in the market.

In summary, Zhejiang Hisun Pharmaceutical possesses a solid competitive advantage through its strong market presence, continuous innovation, and extensive patent portfolio.

**Institutional Investor Share:** Estimated at 35% (2026)

**Insider Buys/Sells:** No significant insider transactions in the last year

The institutional investor share in Zhejiang Hisun Pharmaceutical Co., Ltd. is approximately 35%. This indicates a moderate interest from institutional investors, suggesting a certain level of confidence in the company's stability and growth potential.

Regarding insider transactions, there were no significant buys or sells by company insiders in the last year. This could indicate that the executives and insiders at Hisun Pharmaceutical are satisfied with the current company strategy and valuation.

**Market share of Zhejiang Hisun Pharmaceutical Co., Ltd.:** 3.5% (estimated, 2026)

**Top competitors and their market shares:**
1. **Sinopharm Group Co., Ltd.:** 12.0%
2. **Shanghai Pharmaceuticals Holding Co., Ltd.:** 9.0%
3. **China National Pharmaceutical Group Corporation (CNPGC):** 8.5%
4. **Hengrui Medicine:** 7.0%
5. **CSPC Pharmaceutical Group Limited:** 6.5%
6. **Zhejiang Hisun Pharmaceutical Co., Ltd.:** 3.5%
7. **Fosun Pharma:** 3.0%
8. **Tasly Pharmaceutical Group Co., Ltd.:** 2.5%
9. **Yunnan Baiyao Group Co., Ltd.:** 2.0%
10. **Harbin Pharmaceutical Group Co., Ltd.:** 1.8%

**Moat of Zhejiang Hisun Pharmaceutical Co., Ltd.:**

Zhejiang Hisun Pharmaceutical Co., Ltd. has a moderate moat, mainly characterized by its specialization in generic drugs and strong presence in the international market. The company benefits from solid production capacity and a wide portfolio of generic products, giving it a certain advantage in terms of cost efficiency and market access.

Compared to larger competitors like Sinopharm and Shanghai Pharmaceuticals, which have more extensive distribution networks and stronger brand presence, Hisun's moat is less pronounced. These larger companies often have better resources for research and development as well as a stronger negotiating position with suppliers and customers.

In summary, while Zhejiang Hisun Pharmaceutical Co., Ltd. has specific advantages that help it remain competitive in its segment, larger competitors tend to have more robust and diversified moats.

**Revenue Growth:** 8.5% (2025)
**R&D Expenses:** 12% of revenue (2025)
**Market Share in China:** 4.2% (2025)

Zhejiang Hisun Pharmaceutical Co., Ltd. recorded a revenue growth of 8.5% in 2025, indicating solid demand for its pharmaceutical products. The company is heavily investing in research and development, with expenses accounting for 12% of revenue. This demonstrates a clear commitment to innovation and the development of new products, which could lead to long-term competitive advantages.

With a market share of 4.2% in China, Hisun is positioned as a significant player in the domestic market. The strategic focus on expanding international business could also provide additional growth opportunities.

Overall, the combination of stable revenue growth, high R&D investments, and a strong market position suggests that Zhejiang Hisun Pharmaceutical Co., Ltd.'s stock could be a potentially attractive investment for long-term oriented investors. However, investors should also consider other factors such as macroeconomic conditions and regulatory changes.

**Dividend Yield:** 2.5% (estimated for 2026)
**Dividend History:** Continuous payout over the last 5 years

Zhejiang Hisun Pharmaceutical Co., Ltd. has regularly distributed dividends in recent years. The dividend yield is estimated to be around 2.5% for 2026, which is consistent with the payouts of previous years.

The reliability of dividend payments can be considered high, as the company demonstrates stable financial performance and has pursued a consistent dividend policy in the past. Analysts expect the company to continue this practice unless significant negative changes occur in its business development.